Shopping Cart 0
Cart Subtotal
USD 0

Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies to assist companies in securing prescription drug approvals. It provides a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20

Venture Financing 21

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

Partnerships 22

Ligand Pharma Enters into Agreement with venBio 22

Ligand Pharma Enters into Agreement with AiCuris 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Open Monoclonal Expands Agreement with CNA Development 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30

WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33

Licensing Agreements 34

WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34

Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37

Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38

Amgen Enters into Licensing Agreement with Ligand Pharma 39

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44

Novartis Enters into Licensing Agreement with Ligand Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

TeneoBio Enters into Licensing Agreement with Ligand Pharma 48

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52

RODES Enters into Licensing Agreement with Ligand Pharma 53

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56

Sanofi Enters into Licensing Agreement with Ligand Pharma 57

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58

Open Monoclonal Enters into Licensing Agreement with Celgene 59

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62

Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65

Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74

Ligand Pharma Amends Licensing Agreement with Retrophin 75

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80

Open Monoclonal Enters into Licensing Agreement with Amgen 81

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84

Ligand Pharma Enters Into Licencing Agreement With Merck 85

Equity Offering 86

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD 2.7 Million 86

Ligand Pharma Announces Private Placement Of Common Stock For USD 30 Million 87

Debt Offering 88

Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89

Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91

Acquisition 92

Ligand Pharma Acquires Vernalis 92

Ligand Pharma Acquires Verrow Pharma 94

Ligand Pharma to Acquire Crystal Bioscience 95

Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 97

Ligand Pharmaceuticals Inc-Key Competitors 98

Ligand Pharmaceuticals Inc-Key Employees 99

Ligand Pharmaceuticals Inc-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 102

Financial Announcements 102

Aug 06, 2018: Ligand reports second quarter 2018 financial results 102

May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018 105

Feb 21, 2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results 108

Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 111

Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 114

May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 117

Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 120

Corporate Communications 123

Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 123

Legal and Regulatory 124

Jul 27, 2018: Fr. Emmanuel Lemelson Responds to SEC Charges 124

Other Significant Developments 125

Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 125

Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 126

Appendix 128

Methodology 128

About GlobalData 128

Contact Us 128

Disclaimer 128


List Of Figure

List of Figures

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

Ligand Pharma Enters into Agreement with venBio 22

Ligand Pharma Enters into Agreement with AiCuris 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Open Monoclonal Expands Agreement with CNA Development 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30

WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33

WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34

Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37

Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38

Amgen Enters into Licensing Agreement with Ligand Pharma 39

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44

Novartis Enters into Licensing Agreement with Ligand Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

TeneoBio Enters into Licensing Agreement with Ligand Pharma 48

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52

RODES Enters into Licensing Agreement with Ligand Pharma 53

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56

Sanofi Enters into Licensing Agreement with Ligand Pharma 57

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58

Open Monoclonal Enters into Licensing Agreement with Celgene 59

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62

Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65

Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74

Ligand Pharma Amends Licensing Agreement with Retrophin 75

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80

Open Monoclonal Enters into Licensing Agreement with Amgen 81

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84

Ligand Pharma Enters Into Licencing Agreement With Merck 85

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD 2.7 Million 86

Ligand Pharma Announces Private Placement Of Common Stock For USD 30 Million 87

Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89

Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91

Ligand Pharma Acquires Vernalis 92

Ligand Pharma Acquires Verrow Pharma 94

Ligand Pharma to Acquire Crystal Bioscience 95

Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 97

Ligand Pharmaceuticals Inc, Key Competitors 98

Ligand Pharmaceuticals Inc, Key Employees 99

Ligand Pharmaceuticals Inc, Subsidiaries 100

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ligand Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies to assist companies in securing prescription drug approvals. It provides a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20

Venture Financing 21

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

Partnerships 22

Ligand Pharma Enters into Agreement with venBio 22

Ligand Pharma Enters into Agreement with AiCuris 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Open Monoclonal Expands Agreement with CNA Development 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30

WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33

Licensing Agreements 34

WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34

Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37

Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38

Amgen Enters into Licensing Agreement with Ligand Pharma 39

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44

Novartis Enters into Licensing Agreement with Ligand Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

TeneoBio Enters into Licensing Agreement with Ligand Pharma 48

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52

RODES Enters into Licensing Agreement with Ligand Pharma 53

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56

Sanofi Enters into Licensing Agreement with Ligand Pharma 57

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58

Open Monoclonal Enters into Licensing Agreement with Celgene 59

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62

Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65

Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74

Ligand Pharma Amends Licensing Agreement with Retrophin 75

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80

Open Monoclonal Enters into Licensing Agreement with Amgen 81

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84

Ligand Pharma Enters Into Licencing Agreement With Merck 85

Equity Offering 86

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD 2.7 Million 86

Ligand Pharma Announces Private Placement Of Common Stock For USD 30 Million 87

Debt Offering 88

Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89

Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91

Acquisition 92

Ligand Pharma Acquires Vernalis 92

Ligand Pharma Acquires Verrow Pharma 94

Ligand Pharma to Acquire Crystal Bioscience 95

Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 97

Ligand Pharmaceuticals Inc-Key Competitors 98

Ligand Pharmaceuticals Inc-Key Employees 99

Ligand Pharmaceuticals Inc-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 102

Financial Announcements 102

Aug 06, 2018: Ligand reports second quarter 2018 financial results 102

May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018 105

Feb 21, 2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results 108

Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 111

Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 114

May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 117

Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 120

Corporate Communications 123

Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 123

Legal and Regulatory 124

Jul 27, 2018: Fr. Emmanuel Lemelson Responds to SEC Charges 124

Other Significant Developments 125

Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 125

Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 126

Appendix 128

Methodology 128

About GlobalData 128

Contact Us 128

Disclaimer 128


List Of Figure

List of Figures

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

Ligand Pharma Enters into Agreement with venBio 22

Ligand Pharma Enters into Agreement with AiCuris 23

Symphogen Enters Into Agreement With Open Monoclonal Technology 24

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Open Monoclonal Expands Agreement with CNA Development 27

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30

WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33

WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34

Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35

Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37

Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38

Amgen Enters into Licensing Agreement with Ligand Pharma 39

Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40

xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41

Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43

CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44

Novartis Enters into Licensing Agreement with Ligand Pharma 45

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47

TeneoBio Enters into Licensing Agreement with Ligand Pharma 48

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52

RODES Enters into Licensing Agreement with Ligand Pharma 53

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56

Sanofi Enters into Licensing Agreement with Ligand Pharma 57

Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58

Open Monoclonal Enters into Licensing Agreement with Celgene 59

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62

Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65

Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74

Ligand Pharma Amends Licensing Agreement with Retrophin 75

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80

Open Monoclonal Enters into Licensing Agreement with Amgen 81

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84

Ligand Pharma Enters Into Licencing Agreement With Merck 85

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For USD 2.7 Million 86

Ligand Pharma Announces Private Placement Of Common Stock For USD 30 Million 87

Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88

Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89

Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91

Ligand Pharma Acquires Vernalis 92

Ligand Pharma Acquires Verrow Pharma 94

Ligand Pharma to Acquire Crystal Bioscience 95

Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 97

Ligand Pharmaceuticals Inc, Key Competitors 98

Ligand Pharmaceuticals Inc, Key Employees 99

Ligand Pharmaceuticals Inc, Subsidiaries 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ligand Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.